Axsome Therapeutics, based in New York City, develops therapies for central nervous system disorders, with commercial products Auvelity and Sunosi, and investigational drugs AXS-05 and AXS-07. The company employs 545 staff and went public in November 2015.
Mark Coleman sold 3,750 shares of AXSM on 28 May at $103.43 per share, worth a total of $388K. They now own 46,637 AXSM shares, or a 7% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!